+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 45Years - 80Years
All Genders
ID06884865

Evaluating the Safety and Tolerability of PCRX-201 Injection in Adults with Painful Knee Osteoarthritis

Led by Pacira Pharmaceuticals, Inc · Updated on 2026-08-25

135

Participants Needed

40

Research Sites

295 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying osteoarthritis of the knee in adults aged 45 to 80 years to evaluate the safety, tolerability, and effects of a single knee injection of PCRX-201 following steroid pretreatment. This Phase 2 trial compares two different doses of PCRX-201 to placebo over one year, focusing on adverse events and treatment impact on knee pain and joint function. Participants will be randomly assigned to receive one of the PCRX-201 doses or placebo after pretreatment with methylprednisolone acetate. The study has two parts, with Part A involving 45 subjects and Part B enrolling 90 subjects, each stratified by disease severity. The injections are given as a single intra-articular dose, and the study drug is manufactured by two different processes. Participants will visit the clinic for pretreatment, drug administration, and multiple follow-ups throughout the study. Visits are weekly or biweekly initially, then monthly until one year, with additional visits up to five years. Researchers will monitor adverse events, measure PCRX-201 levels in blood and skin samples, assess immune response and inflammation markers, and evaluate changes in knee pain and function using standardized scales.

CONDITIONS

Brief Title

A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

Research Team

L

Lisa Ramsay, MA

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here